Printer Friendly

PROCYTE PHARMACEUTICAL DEVELOPMENT EXEC RESIGNS

 KIRKLAND, Wash., July 19 /PRNewswire/ -- ProCyte Corp. (NASDAQ-NMS: PRCY) announced today the resignation of its recently hired vice president of pharmaceutical development, Dr. Michael Dey. Dey resigned for undisclosed personal reasons. Dey's responsibilities will temporarily be assumed by Dr. Ron Warner until such time that a replacement is named.
 -0- 7/19/93
 /CONTACT: Karen L. Hedine, vice president, of ProCyte, 206-820-4548/
 (PRCY)


CO: ProCyte Corp. ST: Washington IN: MTC SU: PER

SB-JH -- SE010 -- 3213 07/19/93 16:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 19, 1993
Words:81
Previous Article:RHONE-POULENC RORER REPORTS GOOD SECOND QUARTER EARNINGS GROWTH
Next Article:COMMERCIAL BANCORP REPORTS RECORD SECOND QUARTER EARNINGS
Topics:


Related Articles
PROCYTE CORP. REPORTS FIRST-QUARTER FINANCIALS
PROCYTE CORPORATION NAMES TWO NEW CORPORATE OFFICERS
PROCYTE CORP. REPORTS SECOND QUARTER FINANCIALS
PROCYTE CORP. REPORTS THIRD QUARTER FINANCIALS; CLINICAL PROGRAMS PROGRESSING ON SCHEDULE
PROCYTE ANNOUNCES CONSTRUCTION HAS BEGUN ON REDMOND PLANT
PROCYTE LICENSES WOUND HEALING TECHNOLOGY TO PARTNER IN JAPAN
PROCYTE CORP. STOCK OFFERING EFFECTIVE
PROCYTE DRUG PREVENTS HAIR LOSS THAT RESULTS FROM CHEMOTHERAPY TREATMENT
PROCYTE REPORTS 1993 FOURTH QUARTER RESULTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters